Anticonceptivos Orales Combinados, Bibliografía

Bibliografía Anticonceptivos Orales combinados 

Dr. Álvaro Monterrosa Castro, M.D

  1. Bagshaw S. the combined oral contraceptives. Risk and adverse effects in perspective. Drug-Saf 1995; 12 (2): 91 – 96.
  2. American Collage of Obstetricians and Gynecologist. Hormonal contraception. ACOG technical bulletin Nº. 198 – October de 1994 Int J Gynaecol Obstet 1995; 48 (1): 115 – 126.
  3. Mishell Jr DR. Oral contraception: past, present and future perspectives. Int J Fertil 1992; 37 (1) Suppl: 7 – 18.
  4. Melo NR, Pinotti J.Advances in hormonal contraception. Adv. in contraception 1994; 10 (suppl 1): 33 – 39.
  5. Winkler UH, Schindler AE, Endrikat J, et al. A comparative study of the effects of the hemostatic system of two monophasic Gestodene oral contraceptive containing 20 ug and 30 ug Etinil-Estradiol. Contraception 1996; 53: 75 – 84.
  6. Coenen CMH, Thomas CMG, Borm GF, et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996; 53: 171 – 176
  7. Wilde MI, Balfour JA. Gestodeno. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparation. Drug 1995; 50 (2): 364 – 395.
  8. Monterrosa A. Anticoncepción hormonal. EN : Caraballo J, Parra E, Taylor H. Memorias del 1º Curso de actualización en Ginecología y Pediatría. Imprenta U. de Cartagena. Cartagena.1994; 241 – 250.
  9. Hannaford PC, Combined oral contraceptives: do we know all of their effects. Contraception 1995; 51: 325-327.
  10. Rosenberg MJ, Waugh MS, Meehan T. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283- 288.
  11. Harlap S. Benefits and risks of birth control in U.S. Women. Int J fertil 1992; 37 (suppl 3): 148 – 156
  12. Lidegaard O, Milsom I. Oral contraceptives and Thrombotic diseases. Impact of new epidemiological studies Contraception 1996; 53: 135 – 139
  13. Word Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception. Ischaemic stroke and combined oral contraceptives : results of an international. Multicentre case control study. Lancet 1996; 348: 498 – 505
  14. Urdinola J, Gutierrez A, Londoño D. Anticonceptivos orales en America Latina. Adv. in contraception 1993; 9 (suppl 1): 3 – 12.
  15. Thorogood M, Vessey MP. Treds in use of oral contraceptives in Britain Br J Fam 1990; 16: 41-53.
  16. Rosenberg MJ, Burnhill MS, Waugh MS, et al. Compliance and oral contraceptives: a Review Contraception 1995; 52: 137-141
  17. Rosenberg MJ, Waugh MS, Higgins JE. The effect of Desogestrel, Gestodene and other factors on spotting and bleeding. Contraception 1996; 53: 85 – 90.
  18. Coata G, Ventura F, Lombardini R, et al. Effect of low dose oral Tripasic contraceptives on blood viscosity, coagulation and lipid metabolism Contraception 1995; 52: 151 – 157
  19. Porte Jr W.C., Waife R.S., Holtrp H.R. Manual de anticoncepción para personal de salud. Pathfinder Found 2º Edición. Bogotá. 1988
  20. Stubblefield PG. anticoncepción. EN : Ginecología. Copeland. Ed. Editorial Médica Panamericana. Buenos Aires 1994; 151 – 184.
  21. Darney P. Safety and efficacy of a Tripasic oral contraceptive containing Desogestrel: results of three multicenter trial. Contraception 1993; 48: 323 – 327
  22. Profamilia. Historia de los métodos anticonceptivos. Cuadernillo estudiantil. Centro documentación Profamilia. Bogotá. 1993
  23. Sánchez Torres F. La anticoncepción. EN : Ciencia y reproducción humana. Empresa editorial Universidad Nacional de Colombia. Bogotá. 1991; 83 – 99
  24. Pincus G, Rock J, Garcia CR, et al. Fertility control with oral medication. Am J Obstet Gynecol 1958; 75: 1333 – 1346.
  25. Urdinola J. Anticonceptivos orales : 30 vs 20 ug de Etinil-Estradiol. Adv. in contraception 1994; 10 (suppl 1): 41 – 49.
  26. Petterson CM. Progestágenos, antagonistas de la progesterona, progesterona y andrógenos : síntesis, clasificación y uso. Clínicas Obstétricas y Ginecológicas. 1995; 4: 783 – 790.
  27. Smith H, Hughes GA, Douglas GH, et al. Totally synthetic -13-alkyl- 3- hydroxy and methoxy – Gona – 1, 3, 5 (10) – trien – 17- ones and related compounds. Experiential 1963; 19: 394 – 396.
  28. Rufer C, Kosmol H, Schroder E, et al. Total synthese von optisch aktiven 13 – athhyl – gonan – derivaten. Liebigs. An Chem. 1967; 702: 141 – 148
  29. Lanes SF, Birmann B, Walker AM, et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992; 166: 956 – 961.
  30. Stubblefield PG. Selección del mejor anticonceptivo oral. Clínicas Obstétricas y Ginecológicas. 1989; 2: 307 – 318.
  31. Woods J. Oral contraceptives and hypertension. Lancet 1967; 2: 653-654
  32. Inman WHW, Vessey MP, Westherholm B, et al. Thromboembolic disease and the steroids content of oral contraceptives: A report to the committee on the safety of drug. Br Med J 1970; 2: 203 – 210.
  33. Darney PD. Combination oral contraceptives and cardiovascular disease Seminars in Reprod Endocrinol 1996; 14(1): 51 – 61
  34. Grimes D. The safety of oral contraceptives: epidemiologic insights from the first 30 years. Am J Obstet Gynecol 1992; 188: 1950 – 1954.
  35. Trossarelli GF, Gennarelli G, Benedetto C, et al. Climacteric symptoms and control of the cycle in women aged years or older taking an oral contraceptive with 0.150 mg Desogestrel and 0.020 mg Etinil-Estradiol. Contraception 1995; 51: 13-18
  36. Kay CR. The happiness pill?. JR Collgen Proct 1980; 30: 8 – 12.
  37. Lachnit- fixon V. Erstes dreistufenpapaarat zur hormonalen konseptions verttutung. Munchen Med WSchr 1979; 121: 1419 – 1424.
  38. Chez RA. Clinical aspects of three new progestagens: Desogestrel, Gestodeno, Norgestimate. Am J Obstet Gynecol 1989; 160: 1296 – 1300.
  39. Mercilon a new low dose combined oral contraceptive. DTB. 1989; 27: 51 – 52.
  40. Cilest – a combined OC. DTB. 1991; 29: 103 – 104.
  41. Urdinola J, Alwers R. Clinical aspects of the new contraceptive pill with Gestodene. Gynecol Endocrinol 1991; 5(2): 7 – 22.
  42. Andolsek K. Cycle control with triphasic Norgestimate and Etinyl estradiol, a new oral contraceptive age. Acta Obstet Gynecol Scand 1992; 71 (156, suppl): 22 – 26.
  43. Burkman RT, Kafrissen ME, Olson W. Lipid and carbohydrate effects of a new Triphasic oral contraceptive containing Norgestimate. Acta Obstet Gynecol Scand 1992; 71: 156 (suppl): 5 – 8.
  44. Jordan VC, Jeng MH, Catherino WH, et al. The estrogenic activity of synthetic progestin used in oral contraceptives. Cancer 1993; 15 (71) suppl: 1501 – 1505.
  45. Fotherby K, Caldwell DS. New progestagens in oral contraception. Contraception 1994; 49: 1 – 32.
  46. Rebor RW, Zeserson K. Characteristic of the new progestagens in combination oral contraceptives. Contraception 1991; 44: 1 -10.
  47. Speroff L, Decherney A. Evaluation of a new generation of oral contraceptive. Obstet Gynecol 1993; 81: 1034 – 1047.
  48. Lal J, Asthana OP, Nityanand S, et al. Pharmacokinetic of Centchroman in healthy female subjects after oral administration. Contraception 1995; 52: 297- 300
  49. Population information program. Lower dose pill. Population Report. 1988 ;Serie A ( 7), 1 – 31.
  50. Uriza G. Planificación familiar. Bogotá. 1994
  51. Drife J. Benefits and risk of oral contraceptives. Adv in Contraception 1990: 6(supl): 15-25
  52. De Leo V, Lanzetta D, Vanni AL, et al. Low estrogen oral contraceptives and the hypothalamus-pituitary axis. Contraception 1991; 44 (2): 155 – 161.
  53. Dericks-Tan JSE, Kock P, Taubert HD. Synthesis and release of gonadotropin: effect of an oral contraceptives. Obstet Gynecol 1983; 62: 687 – 693.
  54. Fitzgerald C, Feichtinger W, Spona J, et al. A comparison of the effects of two monophasic low dose oral contraceptives in the inhibition of ovulation. Contraception 1994; 10: 5 -18.
  55. Thomas K, Vankrieken L. Inhibition of ovulation by low dose monophasic contraceptive containing Gestodene. Am J Obstet Gynecol 1990; 163 (suppl): 1404 – 1410.
  56. Ling WY, Johnston DW, Lea RH, et al. Serum gonadotropin and ovarian steroid levels in women during administration of a Norethindrone, Etinyl-estradiol Tripasic oral contraceptive. Contraception 1985; 32: 367- 370.
  57. Gaspard UJ, Dubios M, Guillain D, et al. Ovarian functions effectively inhibited by a low dose Triphasic oral contraceptive containing Etinyl-estradiol and Levonorgestrel. Contraception 1984; 29: 305 – 309.
  58. London RS, The new era in oral contraception. Pills containing Gestodeno, Norgestimate and Desogestrel. Obstet Gynecol Survey 1992; 47: 777 – 782.
  59. Phillips A. Progestational and androgenic receptor binding affinities and in vivo activities of Norgestimate and other progestines. Contraception 1990; 41 (4): 399 – 410.
  60. Chapdelaine A, Desmarais JL, Derman RJ. Clinical evidence of the minimal androgenic activity of Norgestimate. Int J Fertil 1989; 34: 347 – 352.
  61. Patsch W, Brown SA, Gotto AM Jr, et al. The effect of triphasic oral contraceptives on plasma lipids and lipoproteins. Am J Obstet Gynecol 1989; 161: 1396 – 1401.
  62. Farmer RDT, Lawrenson R. Utilization patterns of oral contraceptives in UK General Practice. Contraception 1996; 53: 211 – 215
  63. Jamin C, Mouzon J. Selective prescribing of third generation oral contraceptives. Contraception 1996; 54: 55- 56
  64. Anonymous. Anticonceptivos orales: cuales comenzar a tomar, cuando y como. Drug and therapeutics bulletin 1991; 30(11): 1 -6.
  65. Rosenberg MJ, Long SC. Oral contraceptives and cycle control: a critical review of the literature. Adv contraception 1992; 8 (suppl 1): 35 – 45.
  66. Fiedman AJ. Thomas PP. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in pre menopausal women with leiomyomas? Obstet Gynecol 1995; 85: 631 – 635
  67. Spinillo A, Capuzzo E, Nicola S, et al. The impact of oral contraception on vulvo vaginal candidiasis. Contraception 1995; 51: 293-297
  68. Meade TW. Risk and mechanism of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol 1988; 158: 1646 – 1652.
  69. Kirhman RJE. Contraception for women over 35. Adv. in contraception 1991; 7 (suppl 1): 48 – 54.
  70. Grupo científico de la OMS. sobre anticonceptivos orales y neoplasia. Anticonceptivos orales y neoplasia. Informe de un grupo científico de la O.M.S. Informes técnicos 1992: No. 817: 1-47.
  71. Derman RJ. An overview of the non contraceptive benefits and risk of oral contraception. Int J Fertil 1992; 37 (1) suppl: 19 -26.
  72. Grubb GS. Women’s perceptions on the safety of the pill: a survey in eight developing countries. J Biosoc Sci 1987; 19: 313 – 321
  73. Balasch J, Calaf J. Riesgos de la contracepción hormonal (con especial referencia a la enfermedad trombo-embolica) Clin Invest Gin Obstet 1996; 23(4): 148 – 157
  74. Sachs DB, Masterson T, Jewett JF. Reproductive mortality in Massachusetts in 1981. New Engl J Med. 1984; 311: 667 – 670
  75. Ory HW, Rosenfiel A, Londmon LC. The pill at 20: an assessment. Fam Plann Perspect 1980; 12: 278 – 288.
  76. Peterson HB, Lee NC. Efectos de los anticonceptivos orales sobre la salud: Malentendidos, controversias y buenas noticias todo el tiempo. Clínicas Obstétricas y ginecológicas 1989; 2: 329 – 343.
  77. Ory HW. The non contraceptive health benefits from oral contraceptive use. Fam Plann Perspect 1982; 14: 182 – 191.
  78. Steinberg WN. Oral contraception: risk and benefits. J Soc Obstet Gynecol Can 1990; 12: 9 – 15.
  79. Tyrer LB. Current controversies and future direction of oral contraception. Curr Opinion Obstet Gynecol 1993; 5: 833 – 838.
  80. Royal College of General Practitioners. Oral contraceptive and health : an interim report from the oral contraception study of the Royal College of General Practitioners. New York, Pittway, 1974, 100 – 130
  81. Drif J. The benefits of combined oral contraceptive. Br J Obstet Gynaecol 1989; 96: 1255 – 1258
  82. Lanes SF, Birmann B, Walker AM, et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992; 166: 956 – 961.
  83. Vessey MP, Metcalfe A, Wells C, et al. Ovarian neoplasm, functional ovarian cysts and oral contraceptives Br Med J 1987; 294: 1518 -1520
  84. Food and Drug Administration. Data in conclusive on birth control pills and ovarian cysts. FDA Talk paper. 1988; junio -15.
  85. Parkin DM et al. Estimates of the world wide frequency of sixteen mayor cancers in 1980. International Journal of cancer 1990. ARC scientific publication Nº 100.
  86. Beck Jr. WW. Use oral Contraceptives in women in their 40S. Postgraduate Obstetrics Gynecology 1995; 15 (12): 1-6
  87. Cancer and steroid hormone study. The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987; 316: 650 – 655.
  88. Centers for Disease Control Cancer and Steroid Hormones Study. Oral contraceptive use and the risk of ovarian cancer. J. Am. Med. Assoc. 1983; 249: 1596 – 1602
  89. The WHO collaborative study of neoplasm and steroid contraceptives. Epitelial ovarian cancer and combined oral contraceptive. Int. J. Epidemiol 1989, 18: 535 – 545.
  90. Beral V, et al. Oral contraceptives use and malignancies of the genital tract. Lancet 1988, 2; 1331 – 1335.
  91. Harlow BL, et al. Case-control study of borderline ovarian tumors : reproductive history and exposure to exogenous female hormones. Cancer Research 1988; 48: 5849 – 5852.
  92. Weiss NS, et al. Incidence of ovarian cancer in relation to the use of oral contraceptives. Inter J Cancer 1981; 28: 669 – 671.
  93. Sanford JL. Oral contraceptives and neoplasia of the ovary. Contraception 1991; 43 : 543 – 556.
  94. Ramcharan S, et al. The Walnut Creek contraception study. A prospective study of the side effects of oral contraceptives. Vol 33. Bethesda. Inst. Nacional de Salud. 1981.(publicación No.8).
  95. Ziel HK. Estrogen’s role in endometrial cancer. Obstet Gynecol 1982 ; 60 : 509 – 515.
  96. Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus. Contraception 1991 ; 43 : 557- 559.
  97. Cancer and Steroid Hormone Study. Combination oral contraceptive use and the risk of endometrial cancer. J. Am. Med. Assoc. 1987 ; 257 (6) : 796-800
  98. Meirik O. La píldora y el cancer de mama : Nueva información. Boletín Médico de la IPPF. 1996 ; 30 (6) : 1-3
  99. Scarff RW, Torloni H. Histological typing of breast tumors, 2º Ed. Ginebra. O.M.S. 1981 (Clasificación Histológica Internacional de Tumores Nº 2).
  100. Ernester VL. The Epidemiology of bening breast disease. Epidemiologic Reviews 1981 ; 3 : 184 – 202.
  101. Thomas DB. The Breast EN : Michal F, Ed. Safety requirements for contraceptives steroid. Cambridge. Cambridge Universisty Press 1989 : 38-68.
  102. Senanayake P, Kramer DG. Contraception and the etiology of pelvic inflammatory disease : New perspectives. Am J Obstet Gynecol 1980 ; 138 : 852 – 857.
  103. Andolsek L, et al. Influence of oral contraceptives on the incidence of premalignant and malignant lesions of the cervix. Contraception 1983 ; 28 : 505 – 519.
  104. Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease Am J Obstet Gynecol 1982; 144 : 630 -638.
  105. Wolner-Hanssem P, Stevensson L, Maroh PA, et al. Laparoscopic finding and contraceptive use in women with sings and syntoms suggestive of acute salpingitis. Obstet Gynecol 1985 ; 66 : 233 – 239.
  106. Washington AE, Gove S, Schachter J, et al. Oral contraceptive, Chlamydea Trachomatis infection and pelvic inflammatory diseases : A word of caution about protection. JAMA. 1985 ; 253 : 2246 – 2251.
  107. Wolner-Hanssen P, Echembach DA, Paavonen J, et al. Decreased risk of symptomatic Chlamydial pelvic inflammatory disease associated with oral contraceptives. JAMA 1990 ; 263 : 54 – 63.
  108. Grimes DA. Reversible contraception for the 1980s. J Med Assoc 1986 ; 25 : 69 – 75
  109. Mol BWJ, Ankum WM, Bossuyt PMN, et al. Contraception and the risk of ectopic pregnancy. A meta analysis. Contraception 1995 ; 52 : 337-341
  110. Standel B. Oral contraceptive and the occurrence of disease. IN : Gregorie AT, Blye RG, eds. Contraceptive steroid. Pharmacology and safety. New York. Plennum Press. 1986 : 3 – 12
  111. Esdolie JM, Horwitz IR. Observational studies of cause effect relationship : an analysis of methodology problems as illustrated by the conflicting date for the role of oral contraceptives in the etiology of rheumatoid arthritis. J Chronic Dis. 1986 ; 10 : 841 – 849.
  112. Vessey MP, Villard D, Yeates D. Oral contraceptive, cigarette smoking and other factors in relation to arthritis. Contraception 1987 ; 35 : 457 – 463.
  113. Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthritis : an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol 1990 ;43 : 1221 – 1230 rheumatoid arthritis. J Chronic Dis 1986 ; 10 : 841 – 849.
  114. Lindsay R, Tohme J, Kauders B. The effect of oral contraceptive use on vertebral bone mass in pre and post menopausal women. Contraception 1986 ; 34 : 333 – 341.
  115. Polatti F, Perotti F, Filippa N, et al. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception 1995 ; 51 : 221-224
  116. Kritz-Silverstein D, Barrett- Conner E. Bone Mineral Density in post menopausal women as determined by prior oral contraceptive use. Am J Public Health 1993 ; 83 : 983-988
  117. Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids. Reduced risk associated with oral contraceptives. Br Med J 1986 ; 293 ; 359 – 362
  118. Friedman AJ, Thomas PP. Does low – dose combination oral contracep- tive use affect uterine size or menstrual flow in pre menopausal women with leiomyomas ? Obstet Gynecol 1995 ; 85 : 631 – 835.
  119. Lobo R, Skinner JB, Lippman JS. Plasma lipids and Desogestrel and Etinil-Estradiol a meta-analysis. Fertil Steril 1996; 65 : 1100-1109
  120. Fotherby K. Update on lipid metabolism and oral contraceptive. Br J Fam Plann 1990 ; 15 (suppl) : 23 -26.
  121. Robinson GE, Bounds W, Mackie Et al. Changes in metabolism induced by oral contraceptives containing Desogestrel and Gestodeno in older women. Contraception 1990 ; 42 : 263 – 273.
  122. Corson SL. Efficacy and clinical profile of a new oral contraceptive containing Norgestimate : U.S. clinical trial. Acta Obstet Gynecol Scand 1990 ; 152 (Suppl) : 25 – 31.
  123. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptives agents on lipid and carbohydrate metabolism. New Engl J Med 1990 ; 323 : 1375 – 1381.
  124. Balasch J. Los nuevos y los viejos progestágenos. Clin Invest Gin Obst 1992 ; 19 : 127 – 138.
  125. Petersen KR, Skouby SO, Vedel P, et al. Hormonal contraception in women with IDDM. Influence in glycometabolic control and lipoprotein metabolism. Diabetes – Care 1995 ; 18 (6) : 800 – 806.
  126. Weinges KF, Wenzel E, Hellstern P, et al. The effects of two phasic oral contraceptives on hemostasis and platelet function. Adv. In contraception 1995 ; 11 : 227-237
  127. Notelovitz M, Levenson I, Mckensie L, et al. The effects of low dose oral contraceptives on coagulation and fibrinolysis in two high risk population : Young female smokers and older pre menopausal women. Am J Obstet Gynecol 1985 ; 152 : 995 – 999.
  128. Word Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception. Venous Thromboembolic disease and combined oral contraceptives : results of international multicentre case control study. Lancet 1995 ; 346 :1575-1581
  129. Word Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception. Effects of different progestogens on low estrogen oral contraceptives on venous Thromboembolic disease. Lancet 1995; 346: 1582 – 1588
  130. Bagwell MA, thompson SJ, Addy Cl, et al. Primary infertility and oral contraceptives steroid use. Fertil Steril 1995; 63 (6) : 1161 – 1166.
  131. Speroff L, Glass RH, Kase NG. Endocrinología Ginecológica e Infertilidad. 3a. edición. Toray S.A. Barcelona 1986; 413- 454.
  132. Hassan J, Kulenthran A, Thum YS. The return of fertility after discontinuation of oral contraception in Malaysian women. Med J Malaysia 1994 ; 49 (4) : 348 – 350.
  133. Vessey MP. Benefits and risk of combined oral contraceptives. Methods Inf Med 1993 ; 32 : 222 – 224.
  134. Godsland IF, Crook D, Devenport M, et al. Relationships between blood pressure oral contraceptive use and metabolic risk markers for cardiovascular disease. Contraception 1995 ; 52 : 143-149
  135. Fuchs N, Duterberg B, Weber-Diehi F. Ythe effect on blood pressure of a monophasic oral contraceptive containing Etinil-Estradiol and Gestodene. Contraception 1995 ; 51 : 335 -339
  136. Dusterberg B, Brill K. Clinical acceptability of monophasic gestodene. Am J Obstet Gynecol 1990 ; 163 : 1398 – 1404.
  137. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing and antimineralocorticoid progestagens, drospirenone, on the renin – aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 1995 ; 80 : 1816 – 1821.
  138. Bracken MP. Oral contraceptive and congenital malformations in offspring. A review and meta analysis of the prospective studies. Obstet Gynecol 1990 ; 76 : 552 562.
  139. Thorogood M, Vessey MP. An epidemiologic survey of cardiovascular disease in women taking oral contraceptives. Am J Obstet Gynecol 1990 ; 163 : 274 – 281.
  140. U.K. National case – control study group. Oral contraceptive use and breast cancer risk in young women. Lancet 1989 ; 1 : 973 :982.
  141. Harlap S. Oral contraceptive and breast cancer. J Reprod Med 1991 ; 36 (5) : 374 – 395.
  142. Collaborative Group on Hormonal Factors in breast cancer. Breast cancer and hormonal contraceptives. Lancet 1996; 347 : 1713 – 1727
  143. Chilvers C.E.D., Deacon JM. Oral contraceptives and breast cancer. Br J Cancer 1990 ; 61 : 1 – 4
  144. Drife J. The contraceptive pill and breast cancer in young women. Br Med J 1989 ; 298 : 1269 – 1270
  145. Brinton LA, Daling JR, Liff JM, et al. Contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995 ; 87 : 827 – 835
  146. Romieu I, Berlin JA. Colditz G. Oral contraceptive and breast cancer. Cancer 1990 ; 66 : 2253 – 2263
  147. Kelsey JL, Berkowitz GS, Breast cancer Epidemiology. Cancer research 1988 ; 48 : 5615 – 5623.
  148. Stanford JL, Thomas DB. Exogenous progestin and breast cancer. Epidemiol Rev 1993 ; 15 : 98 – 107.
  149. Collaborative Group on Hormonal Factors in breast cancer. Breast cancer and hormonal contraceptives further results Contraception 1996 ;54 : 1S-10S.
  150. Brinton LA, Fraumeni JF. Epidemiology of uterine cervical cancer. J. Chronic diseases 1986 ; 39 : 1051 – 1065.
  151. Muñoz N, Bosch FX. Epidemiology of cervical cancer. EN Muñoz N et al : Eds, Human papillomavirus and cervical cancer. Lyon. Centro internacional de investigación sobre el cáncer. 1989 : 9 – 39.(ARC scientific publication) No. 94.
  152. Bau JK, et al. Possible association between benign hepatomas and oral contraceptives. Lancet 1973 ; 2 : 926 – 929.
  153. Prentice RL, Thomas DB. On the epidemiology of oral contraceptives and disease. Adv in cancer research 1987; 49: 285- 301.
  154. Vessey MP. Oral contraception and cancer EN : Filshie M, Guilleband J. eds. Contraception science and practice. Butterworths. London 1989, 52 – 68
  155. Dollenbach-Hellweg G. On the origin and histological structure of adenocarcinoma in women under 5o years of age. Pathology, Research and practice. 1984 ; 179 : 38 -50.
  156. Briton LA, et al. Oral contraceptive use and risk of invasive cervical cancer. Int J Epidemiol 1990 ; 19 : 4- 11.
  157. Persson E, et al. A case-control study of oral contraceptive use in women with adenocarcinoma of the uterine cervix. European J Obstet Gynecol, reproductive biology 1985 ; 26 : 85 – 90.
  158. Parazzini F, et al. Risk factor for adenocarcinoma of the cervix. A case- control study. J Cancer 1988 ; 57 : 201 – 204.
  159. Jones MW, Silverberg SG. Cervical adenocarcinoma in young women : possible relation ship to microglandular hyperplasia and use of oral contraceptives. Obstet Gynecol 1989 ; 73 : 984 – 989.
  160. Delgado M, Sillero M, Martin JM, et al. Contraceptives and cancer of the cervix uteri. Acta Obstet Gynecol Scand 1992 ; 71 : 368 – 376.
  161. Brinton LA. Oral contraceptives and cervical neoplasia. Contraception 1991 ; 43 : 581 – 595.
  162. Gram IT, Macaluso M, Stalsbery H. Oral contraceptive use and the incidence of cervical intraepithelial neoplasia. Am J Obstet Gynecol. 1992 ; 167 : 40 – 44.
  163. Parazzini F et al. Oral contraceptive use and invasive cervical cancer. Int J Epidemiol 1990 ; 19 :259 – 263.
  164. Holly EA, Cress RD, Ahn Dk. Cutaneous melanoma in women III. Reproductive factors and oral contraceptive use. Am J Epidemiology 1995 ; 141 ( 10) : 943 – 950.
  165. Mc Michael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones and colon cancer : a review and hypothesis. J Natural Cancer Institute 1980 ; 65 : 12-1 – 12-7.
  166. Brezmka V, Padmos Z. Coronary heart disease risk factor in women. Eur Heart J 1994 ; 11 : 1571 – 1584.
  167. Drife J. Complicaciones of combined oral contraception. EN : Filshie M, Guilleband J, eds. Contraception science and practice. Butterworths. London. 1989 ; 39 – 51
  168. Croft P, Hanaford PC. Risk factor for acute myocardial infarction in women evidence from the Royal College of General Practitioners oral contraceptive study. Br Med J 1989 ; 298 : 165 – 168.
  169. Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptives estrogen dose and the riesk of deep venous thromboembolic disease. Am J Epidemiol 1991 ; 133 : 32 – 37
  170. Committee on safety of medicines. Combined oral contraceptives and thromboembolism. London. CSM. 1995.
  171. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and non fatal venous Thromboembolic in women using oral contraceptives with differing progestagen components. Lancet 1995 ; 346 : 1589 – 1592
  172. Spitzer WO. The European Agency for the evaluation o f medicinal products. CMP Bulletin 1995 ; 647.
  173. Debate. What are the risk of third generation oral contraceptives ? Human Reprod 1996 ; 11 (4) : 687 – 693
  174. Word Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception. Hemorrhage stroke, overall stroke risk, and combined oral contraceptives. Results of an international multicentre case control study. Lancet 1996 ; 348 : 505- 510
  175. Lidegaard O. Decline in cerebral Thromboembolic among young women after introduction of low dose oral contraceptives : an incidence study for the period 1980-1993. Contraception 1995 ; 52 : 85 – 92
  176. Thorogood M, Mann J, Murphy M, et al. Fatal stroke and use of oral contraceptives a finding from a case control study. Am J Epidemiol 1992 ; 136 : 36 -45
  177. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack : results of a case control study. BMJ 1993 ; 306 ; 956 – 963
  178. Royal College of General Practitioners oral contraceptive study. Further analysis of mortality in oral contraceptives users. Lancet 1981; 1: 541- 547
  179. Mant D, Villard Mackintosh L, Vessey MP, et al. Myocardial infarction and angina pectoris in young women. J Epidemiol Commun Health 1987; 41 : 215 – 219
  180. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women : evidence from the Royal College of General Practitioner’s oral contraception study. Br Med J 1989 ;298 :165 – 168
  181. Realini JP, Goldzieher JW. Oral contraceptives and cardiovascular disease : a critique of the epidemiological studies. Am J Obstet Gynecol 1985 ; 152 : 729 – 738
  182. Thorneycroff IA. Anticonceptivos orales e infarto de miocardio. EN : Aldrighi J, Urdinola J. Hacia un nuevo estándar en la anticoncepción oral. Doyma S.A. España 1990 ; 14- 18
  183. Wahl P, Wolden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. New Engl J Med 1983 ; 308 : 862 – 867
  184. Engel HJ, Engel E, Licchtlen PR. Coronary atherosclerosis and myocardial infarction in young women- role of oral contraceptives. Eur Heart J 1983 ; 4 : 1-6
  185. Anonymous. Improving contraceptive access : Who reviews eligibility criteria for contraceptive use. Out Look 1995; 13(4): 1- 8.
  186. Monterrosa A. Anticoncepción en adolescentes. Actualización Médica permanente. Ascofame. 1996. Cuaderno No. 8 ; 10-17.
  187. López G. Anticoncepción en adolescentes. 2o. seminario Colombiano de sexualidad en la adolescencia (Memorias) Bogotá 1993: 77-82.
  188. Monterrosa A. Una educación para la sexualidad. Rev. Planificación, Población y Desarrollo. (Profamilia). 1994; 11(23): 85-86.
  189. Monterrosa A. Adolescencia : anticoncepcion y embarazo. Tribuna Medica. 1996 ;94(4) :
  190. López G. Embarazo en adolescentes. Rev Planificación, Población y Desarrollo (Profamilia) 1992; 7(19):31-32.
  191. Monterrosa A. Embarazo en adolescentes. El drama de las niñas madres. Rev. Selecta Medica 1994:5(2):7.
  192. Bossenmeyer R. Anticoncepción en la perimenopausia. Crónica del 1º Congreso Latinoamericano de Climaterio. Flascym’95. Bs.As. Argentina. 1995 ; 2-4
  193. McHenry C. Declaración del IMAP sobre anticoncepción para mujeres mayores de 35 años. Boletín médico del IPPF 1995 ; 29 (3) : 1-2.
  194. Castracane VD, Gimpel T, Goldzieher JW. When is it safe to switch From oral contraceptive to hormonal replacement therapy ? Contraception 1995 ; 52 : 371- 376
  195. McHenry C. Declaración del IMAP sobre anticoncepción de emergencia. Boletín Médico de IPPF. 1994 ; 29(6) : 1 – 2.
  196. Trussell J, Ellertson C, Stewart F. The effectiveness of the Yuzpe regimen of emergency contraception. Fam Plann Perspect 1996 ; 28(2) :64.
  197. Grou F, Rodrigues I, the morning-after pill – How long after ? Am. J Obstet Gynecol 1994 ; 171(6) : 1529 – 1534
  198. Consensus statement on emergency contraception. Contraception 1995 ; 52 : 211 – 213
  199. Anonymous. Emergency contraceptive pills : safe and effective but not widely used. Out look. 1996 ;14(2) :1- 6
  200. Von Hertzen H, Van Look P.F.A. Research on new methods of emergency contraception. International Family Planning Perspectives 1996 ; 28 (2) : 62 – 68
  201. Consortium for emergency contraception. Emergency contraceptive pills : Medical and Service Delivery Guidelines. August 1996
  202. Lynn C. Los AO : una opción de emergencia. Network en Español 1996 ; 16(4) :14 – 17
  203. Senanayake P. Emergency contraception : The international Planned parenthood Federation’s experience. Int Fam Plann Perspect 1996 ; 22(2) : 69 – 70
  204. Van Look P.F.A.,Von Hertzen H. Emergency contraception. British Medical Bulletin 1993 ; 49 : 158 – 170
  205. Ho P.C., Kwan M.S.W. A prospective randomized comparison of Levonorgestrel with the Yuzpe regimen in post-coital contraception. Human Reprod 1993 ; 8 : 389 – 392
  206. Back DJ, Orme MLE. Pharmacokinetic drug interaction with oral contraceptives. Clin Pharmacokinetic 1990; 18: 472- 475.1990 ; 6 (suppl) : 15 – 25.
  207. Back DJ, Orme MLE. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990; 18: 472 – 484
  208. Csemiczky G, Alvendal C, Landgren B. Risk for ovulation in women taking a low- dose oral contraceptive (microgynon) when receiving antibacterial treatment with a fluoroquinolone (Ofloxacin). Adv. In contraception 1996; 12: 101- 109
  209. Kuhnz W, Louton T, Humpel M, et al. Influence of high doses of vitamin C on the bioavailability and the serum protein binding of Levonorgestrel in women using a combiantion oral contraceptive. Contraception 1995 ; 51 : 111- 116
  210. Anonymous Asesoramiento en planificación familiar. Como satisfacer las necesidades individuales de las clientes ? Out Look 1995 ; 13(1) : 1- 7
  211. Rosenberg MJ, Waugh Me, Long SL. Unintended pregnancies due to oral contraceptive discontinuation. The neglected consequence of poor OC use. J Reprod Med 1995 ; 40 : 355 – 360.
  212. Endrikat J, Jaques MA, Mayerhofer M, et al. A Twelve-month comparative clinical investigation of two low-dose oral Contraceptives containing 20 ug Ethinylestradiol / 75 ug Gestodene and 20 ug Ethinylestradiol / 150 ug Desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995; 52: 229 – 235.
  213. Dusterberg B, Ellman H, Muller U et al. Three year’s clinical experience with a new low-dose oral contraceptive containing 20 ug ethinylestradiol and 75 ug gestodene: Efficay, cycle control and tolerability. IN: Lopes P, killick Sr (eds). The New option in low-dose oral contraception – Expanding the Gestodene choice. Carnhorth, lancs, England: Parthenon publishing, 1996: 37 –47.
  214. Short M, Endrikat J. A 12- month comparative investigation of reliability, cycle control and tolerance with low-dose oral contraceptives containing 20 ug ethinylestradiol and either 75 ug gestodene or 150 ug desogestrel. IN: Lopes P, killick Sr (eds). The New option in low-dose oral contraception – Expanding the Gestodene choice. Carnhorth, lancs, England: Parthenon publishing, 1996: 37 –47.
  215. Huner A, Kuhnz W, Heger-mahn D, et al. A single dose and 3 month clinical pharmacokinetic study with a new combination oral contraceptive. Advances in contraception 1995;11: 207 – 225.
  216. Winkler UH. Gaspard U, Leidenbergar F. The influence of low-dose oral contraceptive containing 20 ug ethinylestradiol and 75 ug gestodene on lipid and carbohydrate metabolism and hemostasis. IN: Lopes P, killick Sr (eds). The New option in low-dose oral contraception – Expanding the Gestodene choice. Carnhorth, lancs, England: Parthenon publishing, 1996: 49-63.
Anterior Siguiente

CLIC AQUÍ Y DÉJANOS TU COMENTARIO

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *